Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Hux, M"'
Publikováno v:
In Value in Health May 2020 23 Supplement 1:S78-S78
Publikováno v:
In Value in Health May 2019 22 Supplement 2:S67-S67
Autor:
Howard Feldman, Gauthier, S., Hecker, J., Vellas, B., Hux, M., Xu, Y., Schwam, E. M., Shah, S., Mastey, V.
Publikováno v:
Scopus-Elsevier
Objective: To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD. Methods: A total of 290 patients with AD (screening standardiz
Publikováno v:
Journal of Evaluation in Clinical Practice. 8:277-286
Increasingly, clinical research is evaluated on the quality of its statistical analysis. Traditionally, statistical analyses in clinical research have been carried out from a ‘frequentist’ perspective. The presence of an alternative paradigm ‐
Background and Purpose: Outcome in patients hospitalized for acute stroke varies considerably between populations. Within the framework of the GAIN International trial, a large multicenter trial of a neuroprotective agent (gavestinel, glycine antagon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::4dca4205cc423afc6b8974625253b72f
https://eprints.whiterose.ac.uk/615/1/drummondm5.pdf
https://eprints.whiterose.ac.uk/615/1/drummondm5.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
BACKGROUND: Data from the Canadian Study of Health and Aging (CSHA) were used to examine the relation between severity of Alzheimer's disease, as measured by the Mini-Mental State Examination (MMSE), and costs of caring. METHODS: The CSHA was a commu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4017282bd035cc035ac0f9fe27eb2663
https://europepmc.org/articles/PMC1229640/
https://europepmc.org/articles/PMC1229640/
OBJECTIVE: To summarize published data to date by Canadian authors and from Canadian sources on risperidone, a novel neuroleptic indicated in the management of schizophrenia and related psychotic disorders. It was introduced in Canada in 1993. DATA S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51001aea1437b7e879a7d0c4088abb08
https://europepmc.org/articles/PMC1188939/
https://europepmc.org/articles/PMC1188939/
Autor:
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V, Donepezil MSAD Study Investigators Group, Feldman, H, Gauthier, S, Hecker, J, Vellas, B, Hux, M, Xu, Y, Schwam, E M, Shah, S, Mastey, V
Publikováno v:
Neurology; 2004 Aug 24, Vol. 63 Issue 4, p644-650, 7p
Publikováno v:
In Value in Health November 2014 17(7):A449-A449